Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Parkinson's disease.
The trial will enroll about ten patients for a 28-day open-label treatment period. Its primary endpoint is safety and tolerability, with additional measures including pharmacokinetics and relevant biomarkers in plasma and cerebrospinal fluid. Topline results are expected in 2025.
Ventyx Biosciences (Nasdaq: VTYX) ha avviato la somministrazione del trattamento in un trial di Fase 2a per VTX3232 nella malattia di Parkinson precoce. Lo studio ha l'obiettivo di valutare gli effetti del farmaco su biomarcatori pertinenti alla malattia e al target, incluso l'imaging neurochimico PET esplorativo per misurare il suo impatto sull'attivazione microgliale. Questo studio si basa su evidenze che suggeriscono una forte giustificazione meccanicistica per affrontare la neuroinfiammazione guidata da NLRP3 nella malattia di Parkinson.
Il trial arruolerà circa dieci pazienti per un periodo di trattamento aperto di 28 giorni. Il suo obiettivo primario è la sicurezza e la tollerabilità, con ulteriori misure che includono la farmacocinetica e biomarcatori pertinenti nel plasma e nel liquido cerebrospinale. I risultati preliminari sono attesi nel 2025.
Ventyx Biosciences (Nasdaq: VTYX) ha iniciado la administración de dosis en un ensayo de Fase 2a de VTX3232 para la enfermedad de Parkinson temprana. El ensayo tiene como objetivo evaluar los efectos del medicamento sobre biomarcadores relevantes para la enfermedad y el objetivo, incluyendo neuroimágenes PET exploratorias para medir su impacto en la activación microglial. Este estudio se basa en evidencias que sugieren una sólida justificación mecanicista para abordar la neuroinflamación impulsada por NLRP3 en la enfermedad de Parkinson.
El ensayo incluirá aproximadamente diez pacientes para un período de tratamiento abierto de 28 días. Su objetivo primario es la seguridad y la tolerabilidad, con medidas adicionales que incluyen farmacocinética y biomarcadores relevantes en plasma y líquido cefalorraquídeo. Se esperan resultados preliminares para 2025.
Ventyx Biosciences (Nasdaq: VTYX)가 조기 파킨슨 병 치료를 위한 VTX3232의 2a상 임상시험에서 투약을 시작했습니다. 이 시험은 약물의 질병 및 목표 관련 바이오마커에 대한 영향을 평가하는 것을 목표로 하며, 미세아교세포 활성화에 미치는 영향을 측정하기 위해 탐색적 PET 신경 이미징을 포함합니다. 이 연구는 파킨슨병에서 NLRP3 유도 신경염증을 표적으로 하는 강력한 기계적 근거를 제안하는 증거에 기반하고 있습니다.
이 시험은 약 열 명의 환자를 28일 개방형 치료 기간동안 모집할 예정입니다. 주요 목표는 안전성과 내약성이며, 추가 측정에는 약물 동태학과 혈장 및 뇌척수액의 관련 바이오마커가 포함됩니다. 최종 결과는 2025년에 발표될 예정입니다.
Ventyx Biosciences (Nasdaq: VTYX) a lancé la distribution dans un essai de Phase 2a de VTX3232 pour la maladie de Parkinson précoce. L'essai vise à évaluer les effets du médicament sur des biomarqueurs pertinents pour la maladie et le ciblage, y compris l'imagerie PET exploratoire pour mesurer son impact sur l'activation microgliale. Cette étude est fondée sur des preuves suggérant une forte justification mécanistique pour cibler la neuroinflammation induite par NLRP3 dans la maladie de Parkinson.
L'essai recrutera environ dix patients pour une période de traitement ouverte de 28 jours. Son principal objectif est la sécurité et la tolérabilité, avec des mesures supplémentaires comprenant la pharmacocinétique et des biomarqueurs pertinents dans le plasma et le liquide céphalorachidien. Les résultats préliminaires sont attendus pour 2025.
Ventyx Biosciences (Nasdaq: VTYX) hat die Dosierung in einer Phase 2a-Studie zu VTX3232 für frühe Parkinson-Krankheit eingeleitet. Ziel der Studie ist es, die Auswirkungen des Medikaments auf krankheits- und zielrelevante Biomarker zu bewerten, einschließlich explorativen PET-Neuroimagiers, um seine Auswirkungen auf die Mikrogliaktivierung zu messen. Diese Studie basiert auf Beweisen, die eine starke mechanistische Rechtfertigung für die Zielverfolgung der von NLRP3 ausgelösten Neuroinflammation bei Parkinson bieten.
Die Studie wird etwa zehn Patienten für einen 28-tägigen offenen Behandlungszeitraum einschließen. Der primäre Endpunkt ist Sicherheit und Verträglichkeit, wobei zusätzliche Maßnahmen Pharmakokinetik und relevante Biomarker in Plasma und Liquor cerebrospinalis umfassen. Die Hauptergebnisse werden für 2025 erwartet.
- Initiation of Phase 2a trial for VTX3232 in early Parkinson's disease
- Potential to disrupt Parkinson's disease pathology with NLRP3 inhibition in the CNS
- Exploratory PET neuroimaging included to measure impact on microglial activation
- Small sample size of approximately ten patients
- Results not expected until 2025, indicating a long wait for potential progress
The initiation of a Phase 2a trial for VTX3232 in early Parkinson's disease represents a significant step in Ventyx Biosciences' pipeline development. This NLRP3 inhibitor targets neuroinflammation, a key factor in Parkinson's pathogenesis. The trial's focus on biomarkers and PET neuroimaging could provide important early insights into the drug's potential to modify disease progression, a major unmet need in Parkinson's treatment.
However, investors should note that with only ten patients and a 28-day treatment period, this trial is primarily exploratory. While it may offer valuable data on safety and mechanism of action, it's unlikely to provide definitive efficacy results. The 2025 timeline for results also indicates a long path ahead before potential commercialization. This news suggests Ventyx is making progress, but substantial clinical and regulatory hurdles remain.
The focus on NLRP3-driven neuroinflammation in Parkinson's disease is a promising approach. Microglial activation, a hallmark of neuroinflammation, has been increasingly recognized as a potential therapeutic target. VTX3232's mechanism could potentially address both symptoms and disease progression, which current treatments fail to do effectively.
The inclusion of PET neuroimaging to measure microglial activation is particularly noteworthy. This could provide valuable insights into the drug's ability to engage its target in the brain, a critical factor for CNS drugs. However, the small sample size and short duration of the trial may limit its ability to detect meaningful clinical benefits. While this trial is an important first step, larger and longer studies will be necessary to establish VTX3232's efficacy in Parkinson's disease.
For Ventyx Biosciences (NASDAQ: VTYX), this trial initiation represents a strategic expansion into neurodegenerative diseases, potentially broadening its market opportunities beyond inflammatory conditions. However, investors should be cautious about overinterpreting this early-stage development.
The Parkinson's disease market is substantial, with estimates suggesting it could reach
Results from this trial are expected in 2025
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease.
“We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a compelling body of evidence from the literature suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Parkinson’s disease and that microglial NLRP3 activation may play an important role in Parkinson’s disease pathogenesis and neurodegeneration. This trial will evaluate the effects of VTX3232 on disease- and target-relevant biomarkers and will also include exploratory PET neuroimaging to measure the impact of VTX3232 on microglial activation. These measures may provide early insights into the potential of VTX3232 to disrupt Parkinson’s disease pathology with NLRP3 inhibition in the CNS.”
The Phase 2a trial of VTX3232 in early Parkinson’s disease is expected to enroll approximately ten patients for a 28-day open-label treatment period. The trial’s primary endpoint is safety and tolerability. Other outcome measures include pharmacokinetics and relevant biomarkers in plasma and cerebrospinal fluid. We expect to report topline results from this trial in 2025.
About VTX3232
VTX3232 is an oral, selective, CNS-penetrant NLRP3 inhibitor with potential therapeutic utility for a range of neuroinflammatory and neurodegenerative conditions, including Parkinson’s disease, cardiometabolic disease, Alzheimer’s disease, and multiple sclerosis, among others. In the first quarter of this year, we announced results from a Phase 1 trial of VTX3232 in adult healthy volunteers where steady-state exposures achieved with once-daily doses of VTX3232 exceeded the interleukin-1β (IL-1β) IC90 in both plasma and cerebrospinal fluid over 24 hours. We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases.
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies for patients living with inflammatory diseases. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift inflammation markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.
Forward-Looking Statements
Ventyx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Ventyx’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the relationship between NLRP3-driven neuroinflammation and Parkinson’s disease; the relationship between microglial NLRP3 activation and Parkinson’s disease; the potential of VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases; the potential therapeutic utility for VTX3232 in neuroinflammatory and neurodegenerative conditions, including Parkinson’s disease, cardiometabolic disease, Alzheimer’s disease, and multiple sclerosis; the design of the Phase 2a clinical trial of VTX3232 to be conducted by Ventyx, including the total number of patients and total duration of the trial; the ability to measure the disruption of Parkinson’s disease pathology through PET neuroimaging; the timing of clinical updates for the Phase 2a Trial of VTX3232, including the reporting of any topline results from that study in 2025. The inclusion of forward-looking statements should not be regarded as a representation by Ventyx that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Ventyx’s business, including, without limitation: potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, delays in site activations and enrollment of clinical trials; the results of preclinical studies and clinical trials; early clinical trials not necessarily being predictive of future results; the ongoing contributions to scientific literature as pertains to the relationships between NLRP3, neuroinflammation and Parkinson’s disease; unexpected adverse side effects or inadequate efficacy of Ventyx’s product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Ventyx’s ability to obtain and maintain intellectual property protection for its product candidates; the use of capital resources by Ventyx sooner than expected; and other risks described in Ventyx’s prior press releases and Ventyx’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of Ventyx’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on August 8, 2024, and Ventyx’s subsequent filings with the SEC.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Ventyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
FAQ
What is the purpose of Ventyx Biosciences' Phase 2a trial for VTX3232?
How many patients will be enrolled in the VTX3232 Phase 2a trial for Parkinson's disease?
When are the results of the VTYX Phase 2a trial for VTX3232 in Parkinson's disease expected?
What is the primary endpoint of the VTX3232 Phase 2a trial for Parkinson's disease?
